The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Rob Ramsay has had a long standing research commitment to understanding bowel and breast cancer using mouse models with defined genetic defects. These sophisticated models replicate various stages of cancer development and some have profound effects on normal tissue biology. He also uses molecular tools to investigate how genes are controlled. These approaches are providing direct input into the development of therapeutic agents for cancer treatment.
DOES BCL-G, A BH3-ONLY PROTEIN, PLAY A ROLE IN INFLAMMATION-ASSOCIATED COLON CANCER?
Funder
National Health and Medical Research Council
Funding Amount
$418,587.00
Summary
Deregulation of the function of several members of the Bcl-2 family has been shown to be an aggravating factor in autoimmune diseases and cancer. Bcl-G is a new and poorly characterized member of this family. We have produced essential tools to study the physiological function of Bcl-G, and discovered that it plays a role in inflammatory bowel disease. We now plan to investigate its possible role in inflammation-associated colon cancer.?
I am a molecular-cell biologist studying the genetic regulation of intestinal homeostasis in development and disease with the aim of identifying novel molecular targets for the treatment of disease and that can be validated in relevant preclinical mouse models.
This project aims to develop a new therapy for colorectal cancer (CRC). We have already demonstrated that a molecule called PAK1 is the master regulator of several intracellular signalling pathways, and is essential for CRC growth and invasion. We now plan to study whether inhibitors that block PAK1 activity can prevent the growth of human CRC cells in the laboratory or their development into tumours in animals.
Therapeutic Targeting Of The Colorectal Cancer Epigenome
Funder
National Health and Medical Research Council
Funding Amount
$537,045.00
Summary
Enhancer RNAs (eRNAs) are a new class of noncoding RNA molecules that have been linked to diverse functions that impinge on cancer, but their clinical relevance is unknown. Our work shows that distinct eRNAs are expressed in a subset of cancer and predict which cancer will respond to a cancer therapeutic agent called a BET inhibitor. Our proposal uses sophisticated preclinical models and cutting edge technology to investigate the functional role of enhancers and enhancer templated RNA in cancer.
Investigating The Roles Of The Wnt And Notch Signalling Systems In Colon Cancer Crypt Biology
Funder
National Health and Medical Research Council
Funding Amount
$604,439.00
Summary
Colon cancer occurs because of mutations to a tumour suppressor gene. These mutations alter the growth and positional signals for the cancer cells. This project aims to produce a computer model of the regulatory processes in normal colonic cells, to discover why the mutations lead to cancer and to discover rational drug targets for interfering with the growth of colon cancer cells.
Chemotherapy causes a massive depletion of blood-producing cells in the bone marrow. This results in a condition known as myelosuppression that has many harmful side effects for cancer patients. Our aim is to develop a safe and inexpensive approach that will specifically protect the blood-producing cells from chemotherapy but leave the cancer cells sensitive. If this treatment shows significant benefits in mouse models of cancer then the establishment of clinical trials will be initiated.
HDAC3 As A Novel Orchestrator Of Lipid Oxidation In The Intestine And Potential Therapeutic Target In Obesity.
Funder
National Health and Medical Research Council
Funding Amount
$526,365.00
Summary
This application will seek to determine whether blocking the HDAC3 protein, specifically in the intestine, represents a novel way of controlling obesity.